南京奥利墨斯医药科技

Olympus Pharmaceutical is a biotechnology company based in Nanjing, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on protein degradation technologies, specifically Proteolysis-Targeting Chimeras (PROTACs) and molecular glues, to target proteins previously considered undruggable. Founded in 2021 by industry veterans, Olympus Pharma aims to address significant unmet medical needs in oncology and immunology. The company leverages its proprietary platform to build a robust pipeline of next-generation therapeutics. Supported by leading venture capital firms, Olympus Pharma is advancing its research programs toward clinical evaluation. The company's approach combines chemical biology with deep disease insights to create transformative medicines.